The 4 most recent market catalysts affecting $RDNT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on RadNet, Raises Price Target to $79
Barclays analyst Andrew Mok has maintained an 'Overweight' rating on RadNet (RDNT) and raised the price target from $65 to $79. This action signals continued confidence in RadNet's…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
RadNet shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline signifies a strong corporate catalyst for RadNet, driving its shares higher due to exceeding Q2 financial expectations. The positive performance suggests robust deman…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 85
Reported Sunday, RadNet Q2 Adj. EPS $0.29 Beats $0.20 Estimate, Sales $622.720M Beat $608.711M Estimate
RadNet (RDNT) announced Q2 adjusted EPS of $0.29, significantly surpassing the analyst consensus of $0.20, and sales of $622.72 million, also beating the $608.71 million estimate. …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
RadNet's DeepHealth Says It Received FDA 510(k) Clearance For AI-Powered Breast Ultrasound, To Roll Out Across Network Covering Over 700,000 Studies Annually By Year-End
RadNet's FDA clearance for AI-powered breast ultrasound is a strong positive catalyst, validating its investment in advanced diagnostic technology. This will likely lead to improve…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.